Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.47 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 3/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.43 |
| ▸ | PSMB8 | P28062 | 8/20 | 0.41 |
| ▸ | PSMB5 | P28074 | 8/20 | 0.41 |
| ▸ | PSMB9 | P28065 | 4/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | PLAT | P00750 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | KDM6B | O15054 | 1/20 | 0.36 |
| ▸ | KDM4A | O75164 | 1/20 | 0.36 |
| ▸ | KDM5C | P41229 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2636620 | 0.91 | KDM2B (0.41) | ROCK2ROCK1SMYD3GSK3BDYRK1A | |
| Hydrochloric Acid SCHEMBL8130097 | 0.89 | KDM2B (0.41) | ROCK2ROCK1SMYD3GSK3BDYRK1A | |
| SCHEMBL70303 | 0.88 | SMYD3 (0.55) | SMYD3PSMB8PSMB5PSMB9RORC | |
| SCHEMBL30999011 | 0.86 | SMYD3 (0.48) | ROCK2ROCK1SMYD3GSK3BDYRK1A | |
| SCHEMBL71503 | 0.85 | PSMB8 (0.53) | SMYD3PSMB8PSMB5PSMB9RORC | |
| SCHEMBL23921518 | 0.82 | SMYD3 (0.54) | ROCK2ROCK1SMYD3GSK3BDYRK1A | |
| SCHEMBL23921589 | 0.81 | SMYD3 (0.68) | SMYD3PSMB8PSMB5PSMB9RORC | |
| SCHEMBL26052869 | 0.81 | SMYD3 (0.46) | SMYD3PSMB8PSMB5PSMB9RORC | |
| SCHEMBL23921543 | 0.79 | SMYD3 (0.45) | ROCK2ROCK1SMYD3GSK3BDYRK1A | |
| SCHEMBL1058260 | 0.79 | GSK3B (0.46) | SMYD3GSK3BDYRK1APSMB8PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129376-B2 | Piperidine derivatives as inhibitors of stearoyl-CoA desaturase | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-03-06 | — | — | US | claimed |
| WO-2009117676-A2 | NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | WO | claimed |
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | US | claimed |
| US-20210317113-A1 | 1,2,3-TRIAZOLE DERIVATIVES AND USES THEREOF | Alxerion Biotech LLC | 2021-10-14 | — | — | US | disclosed |
| US-10973810-B2 | Methods for the treatment of neurological disorders | YUMANITY THERAPEUTICS, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| EP-3566055-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Yumanity Therapeutics, Inc. (US) | 2019-11-13 | — | — | EP | disclosed |
| US-20180193325-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2018-07-12 | — | — | US | disclosed |
| WO-2018129403-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | YUMANITY THERAPEUTICS (US) | 2018-07-12 | — | — | WO | disclosed |
| US-8129376-B2 | Piperidine derivatives as inhibitors of stearoyl-CoA desaturase | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-03-06 | — | — | US | disclosed |
| WO-2009117676-A2 | NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | WO | disclosed |
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10973810-B2 | Methods for the treatment of neurological disorders | NLN, CLN6, OTC | ROCK2 2269/4885ROCK1 3087/4885SMYD3 2701/4885 |
| US-20210317113-A1 | 1,2,3-TRIAZOLE DERIVATIVES AND USES THEREOF | CYP3A43, CYP51A1, CYP11B2 | ROCK2 1412/4885ROCK1 1529/4885SMYD3 2657/4885 |
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | SCD, SCD5, FADS2 | ROCK2 1749/4885ROCK1 2296/4885SMYD3 269/4885 |
| US-20180193325-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NLN, CLN6, OTC | ROCK2 2269/4885ROCK1 3087/4885SMYD3 2701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.